The reverse split is a mechanical adjustment with no fundamental impact. Monitor for any Nasdaq compliance updates or subsequent capital-raising activities that may follow the consolidation.
Price Chart
Executive Summary
Alterity Therapeutics completed a 50-to-1 reverse stock split, reducing outstanding ordinary shares to 217,508,862. The consolidation was approved by shareholders on May 29, 2026, and normal trading commenced June 12, 2026. This is a routine capital structure adjustment with no change to the company's fundamental value or business operations.
Key Facts
- Reverse stock split completed on a 50-to-1 basis, effective June 12, 2026
- Post-consolidation ordinary shares: 217,508,862
- Shareholder approval obtained at General Meeting on May 29, 2026
- Fractional entitlements rounded up to nearest whole number
- Normal trading commenced June 12, 2026 on ASX under code ATH
Financial Impact
No financial impact — reverse split adjusts share price proportionally without changing market capitalization or enterprise value
Risk Factors
- Reverse splits can signal financial distress or listing compliance issues, though the filing does not cite any specific deficiency
- Post-split share price may face selling pressure from retail holders adjusting to the new nominal price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-020373 |
| Document: athe20260612_6k.htm | 0001437749-26-020373 |
| Document: 0001437749-26-020373-index-headers.html | 0001437749-26-020373 |
| Document: 0001437749-26-020373-index.html | 0001437749-26-020373 |
| Document: 0001437749-26-020373.txt | 0001437749-26-020373 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.20 (−5.26%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.20 (+5.26%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.20 (+5.26%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.20 (−7.95%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.20 (−7.95%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.20 (−9.47%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.20 (−29.49%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.20 (−31.68%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.20 (−31.68%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.20 (−40.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers